ERBB2 and cancer: The Cancer Genome Atlas (TCGA) dataset shows that mutations occur in a variety of cancers; bladder cancer has the highest prevalence of HER2 mutations (9–18%), followed by uterine cervix (6%), colorectal (5.8%), lung (4%) and breast (4%) [177].